Cochrane Review Finds Minimal Benefit and Risks in New Alzheimer's Drugs
A comprehensive overview study by the British organization Cochrane indicates that new Alzheimer's drugs, including lecanemab and donanemab, offer hardly any clinically relevant benefit while posing potential health risks. The analysis evaluated 17 clinical studies involving over 20,000 patients with mild cognitive impairment or dementia. Lead author Francesco Nonino stated that despite statistically significant results in previous trials, there is no compelling evidence of meaningful clinical improvement in symptoms or daily functioning after 18 months of treatment. Conversely, patients treated with these antibodies experienced slightly higher rates of brain swelling and cerebral hemorrhages compared to those on placebos. These findings align with recent assessments by Germany’s Federal Joint Committee (G-BA), which found no proven additional benefit over older symptomatic treatments. Consequently, experts recommend shifting focus to other mechanisms of action in drug development. While the drugs are restricted in the EU to patients with specific genetic profiles to mitigate side effects, the study highlights the urgent need for further research into long-term effects and alternative therapeutic approaches for Alzheimer's disease.
Wire timeline
Cochrane Review Finds Minimal Benefit and Risks in New Alzheimer's Drugs
A comprehensive overview study by the British organization Cochrane indicates that new Alzheimer's drugs, including lecanemab and donanemab, offer hardly any clinically relevant benefit while posing potential health risks. The analysis evaluated 17 clinical studies involving over 20,000 patients with mild cognitive impairment or dementia. Lead author Francesco Nonino stated that despite statistically significant results in previous trials, there is no compelling evidence of meaningful clinical improvement in symptoms or daily functioning after 18 months of treatment. Conversely, patients treated with these antibodies experienced slightly higher rates of brain swelling and cerebral hemorrhages compared to those on placebos. These findings align with recent assessments by Germany’s Federal Joint Committee (G-BA), which found no proven additional benefit over older symptomatic treatments. Consequently, experts recommend shifting focus to other mechanisms of action in drug development. While the drugs are restricted in the EU to patients with specific genetic profiles to mitigate side effects, the study highlights the urgent need for further research into long-term effects and alternative therapeutic approaches for Alzheimer's disease.
Aktuell - FAZ.NET